MISAGO RX Self-expanding Peripheral Stent
Terumo Medical Corporation · Decision date Sep 12, 2025
What did the FDA decide?
FDA records P140002/S030 as a supplement to PMA P140002, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 12, 2025.
FDA approval order statement
changes to the endotoxin test procedures and the addition of a lubricant to non-patient-contacting components
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 12, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P140002/S030
- Regulatory pathway
- PMA supplement
- Applicant
- Terumo Medical Corporation
- Product code
- NIP
- Decision code
- OK30
- Decision date
- Sep 12, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.
- Applicant
- Terumo Medical Corporation
- Product code
- NIP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P140002/S029 · Related supplement
MISAGO RX Self-expanding Peripheral Stent; R2P Misago RX Self-expanding Peripheral Stent System
P140002/S030 received
Application receipt date recorded by FDA.
P140002/S030 · FDA decision
30-Day Notice
P140002/S031 · Related supplement
MISAGO RX Self-expanding Peripheral Stent
P140002/S033 · Related supplement
MISAGO RX Self-expanding Peripheral Stent
P140002/S032 · Related supplement
MISAGO(TM) RX Self-expanding Peripheral Stent
Timeline entries are records held by MedtechLedger for P140002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Terumo Medical Corporation | PMA supplement | Aug 5, 2025 | FDA | |
MISAGO RX Self-expanding Peripheral StentP140002/S031 | Terumo Medical Corporation | PMA supplement | Dec 12, 2025 | FDA |
MISAGO RX Self-expanding Peripheral StentP140002/S033 | Terumo Medical Corporation | PMA supplement | Feb 13, 2026 | FDA |
MISAGO(TM) RX Self-expanding Peripheral StentP140002/S032 | Terumo Medical Corporation | PMA supplement | Jul 16, 2026 | FDA |
Explore the linked device profile
Other records with product code NIP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Supera Peripheral Stent SystemP120020/S037 | Abbott Vascular (Idef Technologies Inc) | PMA supplement | Nov 6, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Cordis US Corporation | PMA supplement | Oct 15, 2026 | FDA | |
| Biotronik AG | PMA supplement | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Terumo Medical Corporation
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 950 Elkton Blvd., Hatagaya, 151-0072
Sources and methodology
- Original FDA record: P140002/S030
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




